The targets of curcumin
H Zhou, CS Beevers, S Huang - Current drug targets, 2011 - ingentaconnect.com
Curcumin (diferuloylmethane), an orange-yellow component of turmeric or curry powder, is a
polyphenol natural product isolated from the rhizome of the plant Curcuma longa. For …
polyphenol natural product isolated from the rhizome of the plant Curcuma longa. For …
EGFR mutations and lung cancer
G da Cunha Santos, FA Shepherd… - Annual Review of …, 2011 - annualreviews.org
Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …
kinase activity that transduces important growth factor signaling from the extracellular milieu …
[HTML][HTML] Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert… - New England journal …, 2011 - Mass Medical Soc
Background Trastuzumab improves survival in the adjuvant treatment of HER-positive breast
cancer, although combined therapy with anthracycline-based regimens has been …
cancer, although combined therapy with anthracycline-based regimens has been …
Quinoline as a privileged scaffold in cancer drug discovery
VR Solomon, H Lee - Current medicinal chemistry, 2011 - ingentaconnect.com
Quinoline (1-azanaphthalene) is a heterocyclic aromatic nitrogen compound characterized
by a double-ring structure that contains a benzene ring fused to pyridine at two adjacent …
by a double-ring structure that contains a benzene ring fused to pyridine at two adjacent …
[PDF][PDF] Biocompatible quantum dots for biological applications
Semiconductor quantum dots are quickly becoming a critical diagnostic tool for discerning
cellular function at the molecular level. Their high brightness, long-lasting, size-tunable, and …
cellular function at the molecular level. Their high brightness, long-lasting, size-tunable, and …
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
D Gajria, S Chandarlapaty - Expert review of anticancer therapy, 2011 - Taylor & Francis
HER2 amplification is seen in up to 20% of breast cancers and is associated with an
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since …
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since …
Treatment of non–small-cell lung cancer with erlotinib or gefitinib
VD Cataldo, DL Gibbons, R Pérez-Soler… - … England Journal of …, 2011 - Mass Medical Soc
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein
Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and
epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 …
epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 …
Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent
The synthesis of some 2-furano-4 (3H)-quinazolinones, diamides (open ring quinazolines),
quinoxalines and their biological evaluation as antitumor agents using National Cancer …
quinoxalines and their biological evaluation as antitumor agents using National Cancer …